MOUNTAIN VIEW, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that it has submitted its New Drug Application ...
PALO ALTO, Calif., Nov. 5 AlexzaPharmaceuticals, Inc. (Nasdaq: ALXA) and Autoliv ASP Inc., the North Americansubsidiary of Sweden-based Autoliv Inc. (NYSE: ALV and SSE: ALIV), todayannounced the ...
- UCB to have world-wide rights to Staccato® Alprazolam and would perform further clinical development, submission, launch and commercialization of Staccato® Alprazolam - Initial upfront payment of ...
MOUNTAIN VIEW, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has consolidated its operations, with a ...
NEW ORLEANS, May 26 Results of clinical studies in patients with schizophrenia or bipolar disorder demonstrated that Staccato® loxapine (AZ-004) reduced agitation in patients, regardless of the level ...
"This is the fifth product candidate using our single-dose Staccato technology platform that has completed a Phase 1 clinical trial," said James V. Cassella, PhD, Senior Vice President of R&D at ...
About AZ-002 (Staccato alprazolam) AZ-002 is the combination of Alexza's proprietary Staccato system with alprazolam, a drug belonging to the class of compounds known as benzodiazepines. In a ...
"We previously announced initial results with AZ-104 in an in-clinic setting, showing its positive effect treating pain and other key symptoms of migraine headache," said Thomas B. King, Alexza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback